In addition, we identified several drugs for the treatment of NAFLD along with five potential therapeutic targets (ENO3, CXCL10, INHBE, LRRC31, and OPTN). This evidence concerns the gene LRRC31 and metabolic dysfunction-associated steatotic liver disease.